Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 8/20 | 0.66 |
| ▸ | DRD2 | P14416 | 8/20 | 0.66 |
| ▸ | DRD3 | P35462 | 8/20 | 0.66 |
| ▸ | DRD5 | P21918 | 7/20 | 0.66 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | METAP1 | P53582 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595448 | 0.98 | — | — | |
| SCHEMBL6903663 | 0.98 | DRD1 (0.68) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL6907774 | 0.98 | DRD1 (0.68) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL6900363 | 0.91 | DRD1 (0.74) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL4581239 | 0.86 | METAP1 (0.63) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30777630 | 0.86 | METAP1 (0.63) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL22523888 | 0.85 | DRD2 (0.55) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL4041676 | 0.85 | METAP1 (0.58) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL4895916 | 0.81 | METAP1 (0.61) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL23835146 | 0.80 | METAP1 (0.73) | DRD1DRD2DRD3DRD5METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| CN-104130247-B | Human T 2 R bitterness receptors and application thereof | 塞诺米克斯公司 | 2018-06-01 | — | — | CN | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| CN-103833561-B | The N-arylation method of alkane amine | HENGYANG NORMAL UNIVERSITY (CN) | 2016-01-13 | — | — | CN | disclosed |
| CN-104130247-A | Human T2R bitter taste receptors and the use thereof | SENOMYX INC | 2014-11-05 | — | — | CN | disclosed |
| CN-101828111-B | Human T2R bitter taste receptor and uses thereof | SENOMYX INC | 2014-07-23 | — | — | CN | disclosed |
| CN-103833561-A | Method for N-arylation of alkane amine | UNIV HENGYANG NORMAL | 2014-06-04 | — | — | CN | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008149110-A1 | BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008096129-A1 | NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096127-A2 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USE AS M3 MUSCARINIC RECEPTOR MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008023157-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS M3-RECEPTOR MODULATORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008017827-A2 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017824-A1 | BICYCLO [2. 2. 1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | DRD1 2389/4885DRD2 1404/4885DRD3 1294/4885 |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | DRD1 760/4885DRD2 349/4885DRD3 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.